Radiprodil - GRIN Therapeutics
Latest Information Update: 03 May 2024
At a glance
- Originator GRIN Therapeutics
- Class Antiepileptic drugs; Behavioural disorder therapies; Non-opioid analgesics; Small molecules
- Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Behavioural disorders; Seizures
Most Recent Events
- 30 Apr 2024 GRIN Therapeutics plans a phase Ib/IIa trial for Seizures and Behavioral Symptoms (In children, In adolescents, In infants, Treatment-resistant) in Australia, Belgium, Canada, Italy, Poland, Spain, United Kingdom (PO) (NCT06392009)
- 28 Nov 2022 Phase-I clinical trials in Behavioural disorders (In infants, In children) in Spain, Germany (PO) (EudraCT2022-000317-14)
- 28 Nov 2022 Phase-I clinical trials in Seizures (In children, In infants) in Germany, Spain (PO) (EudraCT2022-000317-14)